GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » EV-to-FCF

Pharmala Biotech Holdings (XCNQ:MDMA) EV-to-FCF : -19.42 (As of May. 29, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmala Biotech Holdings's Enterprise Value is C$17.73 Mil. Pharmala Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.91 Mil. Therefore, Pharmala Biotech Holdings's EV-to-FCF for today is -19.42.

The historical rank and industry rank for Pharmala Biotech Holdings's EV-to-FCF or its related term are showing as below:

XCNQ:MDMA' s EV-to-FCF Range Over the Past 10 Years
Min: -36.12   Med: -14.63   Max: -0.69
Current: -19.92

During the past 3 years, the highest EV-to-FCF of Pharmala Biotech Holdings was -0.69. The lowest was -36.12. And the median was -14.63.

XCNQ:MDMA's EV-to-FCF is ranked worse than
100% of 369 companies
in the Biotechnology industry
Industry Median: 8.9 vs XCNQ:MDMA: -19.92

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Pharmala Biotech Holdings's stock price is C$0.195. Pharmala Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.007. Therefore, Pharmala Biotech Holdings's PE Ratio for today is At Loss.


Pharmala Biotech Holdings EV-to-FCF Historical Data

The historical data trend for Pharmala Biotech Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings EV-to-FCF Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
EV-to-FCF
- -2.04 -22.43

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.06 -31.70 -22.43 -11.03 -17.57

Competitive Comparison of Pharmala Biotech Holdings's EV-to-FCF

For the Biotechnology subindustry, Pharmala Biotech Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's EV-to-FCF falls into.



Pharmala Biotech Holdings EV-to-FCF Calculation

Pharmala Biotech Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=17.729/-0.913
=-19.42

Pharmala Biotech Holdings's current Enterprise Value is C$17.73 Mil.
Pharmala Biotech Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings  (XCNQ:MDMA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmala Biotech Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.195/-0.007
=At Loss

Pharmala Biotech Holdings's share price for today is C$0.195.
Pharmala Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.007.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmala Biotech Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines